Nephraegis Therapeutics is a biopharmaceutical company developing NPH-022 to prevent and treat Acute Kidney Injury (AKI).
Nephraegis Therapeutics is a biopharmaceutical company developing NPH-022 to prevent and treat Acute Kidney Injury (AKI).
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
May 12, 2021 | Seed | — | 1 | Xontogeny | — | Detail |